Pseudomonas Aeruginosa

Animal-Assisted Visitation Program Chlorhexidine Trial

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

PMT for MDRO Decolonization

Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.

Pathobiomes in Gut of Critically Ill Patients

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa

Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)

Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

Clinical Outcomes in Patients With Infection by Resistant Microorganism

Targeted AntiBiotics for Chronic Pulmonary Diseases

Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa

Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)

Open Label Extension to Bridging Study CTBM100C2303

Second Open Label Extension to Bridging Study CTBM100C2303